AI-generated summary
The authors randomly assigned 20 patients with unilateral Ménière's disease to 6 months of low-level laser therapy or betahistine and compared vertigo spells and hearing over time. Both groups showed fewer and shorter spells, with betahistine appearing to act faster at 3 months. The authors conclude laser therapy seems to prevent spells but more slowly than betahistine.
- Participants
- 20
- Who or what was studied
- Patients with unilateral Ménière's disease and uncontrolled vertigo
- Limits stated in the abstract
- The abstract describes a small pilot study, and it notes the laser dose and mechanism are only the authors' interpretation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Pilot study, Statistical significance, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.